Dr. Donal O’Shea

Dr Donal O’Shea is a digital pathology industry veteran having worked for 20 years in academia and commercial within the space.

Donal was co-founder of Slidepath in 2003, one of the pioneering companies in digital pathology application software.   Donal managed the company through to its acquisition by Genetix PLC in 2009.  As part of the management team, Genetix was sold to Danaher Corp in 2010 for $100m.   Within Danaher’s Leica Microsystems and Leica Biosystems operating companies, Donal supported the integration of Genetix, successfully lead various business divisions, launched new products and was significantly involved in the acquisition of Aperio Technologies in 2012, helping to establish Leica Biosystems as the dominant market leader in the space.

Donal has recently founded Deciphex, a company primed to capitalise on the significant interest in application of artificial intelligence in diagnostic pathology.   The company has grown rapidly from its foundation in 2017, attracting capital, filing intellectual property and building key strategic collaborations in healthcare and biopharma.  The company plans to launch its first commercial product in 2019.

Donal has a Ph.D. in computer vision in lifescences and was a HRB Postdoctoral Fellow, assessing the potential of image analysis in the grading and staging of breast cancer.  As an Academic, Donal has supervised and graduated 5 Ph.D. students (3 specifically in digital pathology) and published extensively in the space.  Donal is on the board of a number of Irish start-ups in the lifescience and diagnostics space, including Oncomark, Microsynbiotix and GlowDx.

Major developments in pathology raise many questions. Be part of the discussion on the way forward.

%d bloggers like this: